Cover Image
市場調查報告書

全球大腸躁鬱症(IBS)市場未來趨勢

Global Irritable Bowel Syndrome Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 319668
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
全球大腸躁鬱症(IBS)市場未來趨勢 Global Irritable Bowel Syndrome Market 2015-2019
出版日期: 2014年11月19日 內容資訊: 英文 86 Pages
簡介

大腸躁鬱症(IBS)為消化器官系統中常見的疾病,引起腹部痙攣和不舒服、膨脹感、便秘、腹瀉等症狀。IBS往往被誤診為發炎性腸道疾病(復發性免疫反應和消化管的發炎伴隨的慢性疾病)。IBS的症狀,一般常見於30歲前後的患者。根據CDC,IBS的一般症狀,為極度膨脹感和嚴重胃痙攣與腹痛、腰痛、鼠蹊部痛、胃灼熱、胃酸過多、腿部刺痛、飯後輕微頭痛等。全球大腸躁鬱症市場2014∼2019年的年複合成長率(CAGR)預計達到14.04%。

本報告提供全球的大腸躁鬱症(IBS)治療藥的市場相關分析、市場概要和結構、市場規模趨勢(今後5年的預測值)、各地區的詳細趨勢、推動、阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查、考察。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介

Linzess Irribow/Irribow OD Lotronex Amitiza

第5章 市場調查手法

  • 市場調查流程
  • 調查手法

第6章 簡介

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各作用機制的市場區隔

  • 受體鳥苷酸環化酶-C促效劑
  • 5HT3受體拮抗劑
  • 氯離子通道活化劑
  • 其他

第9章 市場區隔:各劑型

  • 固態劑
  • 液劑

第10章 各適應症的市場區隔

  • IBS-C
  • IBS-D

第11章 終端用戶性別的市場區隔

  • 女性
  • 男女雙方

第12章 地理區隔

第13章 罹患率和盛行率

第14章 購買標準

第15章 市場成長因素

第16章 成長因素與其影響

第17章 市場課題

第18章 成長因素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 業者情勢

  • 競爭模式
    • 主要消息
    • 企業合併、收購(M&A)
  • 市場佔有率分析2014
    • 武田藥品工業
    • Nestle
    • Actavis
    • Astellas Pharma Inc.
  • 其他及未來的有力供應商

第22章 產品研發線

第23章 主要供應商分析

  • Actavis
    • 主要資料
    • 營業內容
    • 產業區分
    • 各部門的市場收益額2012及2013
    • 各地區的銷售額
    • 產業策略
    • 主要資訊
    • SWOT分析
  • Astellas Pharma Inc.
  • Nestle
  • 武田藥品工業

第24章 相關報告

圖表一覽

目錄
Product Code: IRTNTR4709

About Irritable Bowel Syndrome

Irritable bowel syndrome is a common disorder of the digestive system causing abdominal cramps, discomfort, bloating, constipation, and diarrhea. Inflammatory bowel disease, which is a chronic disease with recurrent immune response and inflammation of the GI tract, is sometimes confused with irritable bowel syndrome. The symptoms of irritable bowel syndrome generally appear in a patient aged around 30 years. According to the CDC, prominent symptoms of irritable bowel syndrome include severe bloating, severe stomach cramps or abdominal pain, lower back pain, groin pain, heartburn, acidity, shooting pain in the legs, and lightheadedness after eating.

TechNavio's analysts forecast the Global Irritable Bowel Syndrome market to grow at a CAGR of 14.04 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Irritable Bowel Syndrome market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of irritable bowel syndrome.

TechNavio's report, Global Irritable Bowel Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Irritable Bowel Syndrome market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Actavis
  • Astellas Pharma
  • Nestle
  • Takeda Pharmaceutical

Other Prominent Vendors

  • Abbott
  • Alba Therapeutics
  • Alfa Wassermann
  • Alizyme
  • Almirall
  • AltheRx Pharmaceuticals
  • Ardelyx
  • AstraZeneca
  • Bayer
  • Bristol Myers Squibb
  • Dainippon Sumitomo Pharma
  • Dong-A Socio Holdings
  • Drais Pharmaceuticals
  • Dynogen
  • gIcare Pharma
  • GlaxoSmithKline
  • Hanmi Pharmaceuticals
  • ImmusanT
  • Ironwood
  • Janssen
  • Lexicon Pharmaceuticals
  • Menarini
  • MicroDose Therapeutx
  • Norgine
  • Novartis
  • Ocera Therapeutics
  • Ono Pharmaceutical
  • Par Pharmaceutical
  • Pfizer
  • Pharmos
  • Protagonist Therapeutics
  • RaQualia Pharma
  • Rottapharm
  • Salix
  • Seldar Pharma
  • Shire
  • SK Chemicals
  • SOFAR
  • Synergy Pharmaceuticals
  • Synthetic Biologics
  • Tioga Pharmaceuticals
  • Tsumura
  • Yuhan

Market Driver

  • Presence of Unmet Need
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Therapy
  • For a full, detailed list, view our report

Market Trend

  • Rise in Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Linzess
    • 04.1.2. Irribow/Irribow OD
    • 04.1.3. Lotronex
    • 04.1.4. Amitiza

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Mechanism of Action

  • 08.1. Guanylate Cyclase Receptor-C Agonist
  • 08.2. 5HT3 Antagonist
  • 08.3. Chloride Channel Activator
  • 08.4. Others

09. Market Segmentation by Dosage Form

  • 09.1. Solid
  • 09.2. Liquid

10. Market Segmentation by Indication

  • 10.1. IBS-C
  • 10.2. IBS-D

11. Market Segmentation by End User Gender

  • 11.1. Female
  • 11.2. Both

12. Geographical Segmentation

13. Rate of Incidence and Prevalence

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. Takeda
    • 21.2.2. Nestle
    • 21.2.3. Actavis
    • 21.2.4. Astellas
  • 21.3. Other and Future Prominent Vendors

22. Pipeline Portfolio

23. Key Vendor Analysis

  • 23.1. Actavis
    • 23.1.1. Key Facts
    • 23.1.2. Business Description
    • 23.1.3. Business Segmentation
    • 23.1.4. Business Segmentation by Revenue 2012 and 2013
    • 23.1.5. Sales by Geography
    • 23.1.6. Business Strategy
    • 23.1.7. Key Information
    • 23.1.8. SWOT Analysis
  • 23.2. Astellas Pharma
    • 23.2.1. Key Facts
    • 23.2.2. Business Overview
    • 23.2.3. Product Segmentation
    • 23.2.4. Product Segmentation by Revenue 2012 and 2013
    • 23.2.5. Geographical Segmentation by Revenue 2013
    • 23.2.6. Business Strategy
    • 23.2.7. Recent Developments
    • 23.2.8. SWOT Analysis
  • 23.3. Nestle
    • 23.3.1. Key Facts
    • 23.3.2. Business Overview
    • 23.3.3. Business Segmentation by Revenue 2013
    • 23.3.4. Business Segmentation by Revenue 2012 and 2013
    • 23.3.5. Geographical Segmentation by Revenue 2013
    • 23.3.6. Business Strategy
    • 23.3.7. Recent Developments
    • 23.3.8. SWOT Analysis
  • 23.4. Takeda Pharmaceuticals
    • 23.4.1. Key Facts
    • 23.4.2. Business Overview
    • 23.4.3. Business Segmentation by Revenue 2013
    • 23.4.4. Business Segmentation by Revenue 2013
    • 23.4.5. Geographical Segmentation by Revenue 2013
    • 23.4.6. Business Strategy
    • 23.4.7. Recent Developments
    • 23.4.8. SWOT Analysis

24. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Irritable Bowel Syndrome Market 2014-2019 (US$ million)
  • Exhibit 3: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action
  • Exhibit 4: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action 2014
  • Exhibit 5: Global Irritable Bowel Syndrome Market Segmentation by Dosage Form
  • Exhibit 6: Global Irritable Bowel Syndrome Market Segmentation by Dosage Form 2014
  • Exhibit 7: Global Irritable Bowel Syndrome Market Segmentation by Indication
  • Exhibit 8: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action 2014
  • Exhibit 9: Global Irritable Bowel Syndrome Market Segmentation by End User Gender
  • Exhibit 10: Global Irritable Bowel Syndrome Market Segmentation by End User Gender 2014
  • Exhibit 11: Global Irritable Bowel Syndrome Market by Geographical Segmentation 2014
  • Exhibit 12: Prevalence of Irritable Bowel Syndrome in Japanese Females, by Type
  • Exhibit 13: Prevalence of Irritable Bowel Syndrome in Japanese Males, by Type
  • Exhibit 14: Global Irritable Bowel Syndrome Market Share Analysis 2014
  • Exhibit 15: Pipeline Portfolio of the Drug Candidates for Irritable Bowel Syndrome
  • Exhibit 16: Clinical Trials of Irritable Bowel Syndrome Drugs by Geography
  • Exhibit 17: Clinical Trials of Irritable Bowel Syndrome Drugs by Geography
  • Exhibit 18: Percentage of Clinical Trial Molecules in Each Phase
  • Exhibit 19: Actavis: Business Segmentation 2013
  • Exhibit 20: Actavis: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 21: Actavis : Sales by Geography (in US$ million)
  • Exhibit 22: Astellas Pharma: Product Segmentation 2013
  • Exhibit 23: Astellas Pharma : Product Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 24: Astellas Pharma: Geographical Segmentation by Revenue 2013
  • Exhibit 25: Nestle: Business Segmentation by Revenue 2013
  • Exhibit 26: Nestle: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 27: Nestle: Geographical Segmentation by Revenue 2013
  • Exhibit 28: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
  • Exhibit 29: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
  • Exhibit 30: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
Back to Top